Andes 1537

Drug Profile

Andes 1537

Alternative Names: Andes-1537

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Andes Biotechnologies
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Dec 2015 Andes 1537 is available for licensing as of 24 Dec 2015. http://www.andesbio.com/
  • 01 Dec 2015 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (SC)
  • 16 Apr 2015 Preclinical trials in Solid tumours in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top